236 related articles for article (PubMed ID: 37088816)
41. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
[No Abstract] [Full Text] [Related]
42. Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.
Macro M; Hulin C; Vincent L; Charvet-Rumpler A; Benboubker L; Calmettes C; Stoppa AM; Laribi K; Clement-Filliatre L; Zerazhi H; Honeyman F; Richez V; Maloisel F; Karlin L; Barrak J; Chouaid C; Leleu X
Ann Hematol; 2023 Aug; 102(8):2137-2151. PubMed ID: 37301786
[TBL] [Abstract][Full Text] [Related]
43. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience.
Soyer N; Patır P; Uysal A; Duran M; Ünal HD; Durusoy R; Tombuloğlu M; Şahin F; Töbü M; Vural F; Saydam G
Turk J Med Sci; 2018 Aug; 48(4):777-785. PubMed ID: 30119153
[TBL] [Abstract][Full Text] [Related]
45. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
47. DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Khouri J; Faiman BM; Grabowski D; Mahfouz RZ; Khan SN; Wei W; Valent J; Dean R; Samaras C; Jha BK; Lazarus H; Campagnaro EL; Malek E; Reed J; Karam MA; Hamilton K; Fada S; Kalaycio M; Liu H; Sobecks R; Saunthararajah Y; Chew Y; Orloff M; Reu FJ
Semin Hematol; 2021 Jan; 58(1):45-55. PubMed ID: 33509443
[TBL] [Abstract][Full Text] [Related]
48. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
[No Abstract] [Full Text] [Related]
49. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
[TBL] [Abstract][Full Text] [Related]
50. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
[TBL] [Abstract][Full Text] [Related]
51. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
[TBL] [Abstract][Full Text] [Related]
52. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; DeMarco D; Zhang J; Mei J; Hou J
BMC Cancer; 2016 Jan; 16():46. PubMed ID: 26821931
[TBL] [Abstract][Full Text] [Related]
53. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
[TBL] [Abstract][Full Text] [Related]
54. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Plesner T; Dimopoulos MA; Oriol A; San-Miguel J; Bahlis NJ; Rabin N; Suzuki K; Yoon SS; Ben-Yehuda D; Cook G; Goldschmidt H; Grosicki S; Qin X; Fastenau J; Garvin W; Carson R; Renaud T; Gries KS
Br J Haematol; 2021 Jul; 194(1):132-139. PubMed ID: 33822368
[TBL] [Abstract][Full Text] [Related]
55. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Terpos E; Ntanasis-Stathopoulos I; Gavriatopoulou M; Katodritou E; Hatjiharissi E; Malandrakis P; Verrou E; Golfinopoulos S; Migkou M; Manousou K; Delimpasi S; Symeonidis A; Kastritis E; Dimopoulos MA
Am J Hematol; 2024 Mar; 99(3):396-407. PubMed ID: 38298023
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
Lakshman A; Abeykoon JP; Kumar SK; Rajkumar SV; Dingli D; Buadi FK; Gonsalves WI; Leung N; Dispenzieri A; Kourelis TV; Go RS; Lacy MQ; Hobbs MA; Lin Y; Warsame R; Lust J; Fonder AL; Hwa YL; Hayman SR; Russell SJ; Kyle RA; Gertz MA; Kapoor P
Am J Hematol; 2017 Nov; 92(11):1146-1155. PubMed ID: 28799231
[TBL] [Abstract][Full Text] [Related]
58. Daratumumab plus lenalidomide and dexamethasone
Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
[TBL] [Abstract][Full Text] [Related]
60. [Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].
Zherebtsova VA; Vorobyev VI; Gemdzhian EG; Ulyanova MA; Chernikov MV; Ivanova VL; Vinogradova OY; Ptushkin VV
Ter Arkh; 2021 Jul; 93(7):785-792. PubMed ID: 36286729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]